G7298
Gatifloxacin synthetic
Synonym(s):
Gatifloxacin, (±)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid sesquihydrate sesquihydrate, Tequin®
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C19H22FN3O4 · 1.5H2O
Molecular Weight:
402.42
UNSPSC Code:
51101500
biological source
synthetic
assay
≥98% (HPLC)
form
powder or solid
color
white to light yellow
mp
162 °C
solubility
1 M NaOH: 10 mg/mL
antibiotic activity spectrum
Gram-negative bacteria, Gram-positive bacteria
mode of action
DNA synthesis | interferes, enzyme | inhibits
storage temp.
room temp
General description
Gatifloxacin is a fourth-generation fluoroquinolone which inhbits DNA gyrase and topoisomerase.
Application
Gatifloxacin is a fluoroquinolone antibiotic clinically used to treat bronchitis, sinusitis, community-acquired pneumonia and skin infections. It is used to study potential side effects such as hyperglycemia, seizures and dysglycemia. It is used to study multidrug-resistant organisms.
Biochem/physiol Actions
Gatifloxacin is a fourth-generation fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase, which are necessary for DNA replication, transcription, repair and recombination. It has 100 times higher affinity for bacterial DNA gyrase than for mammalian DNA gyrase. Gatifloxacin is active against both Gram-positive and Gram-negative bacteria.
Legal Information
Tequin is a registered trademark of Bristol-Myers Squibb Co.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Amy R Donaldson et al.
The Annals of pharmacotherapy, 38(4), 602-605 (2004-02-26)
To report a case of possible gatifloxacin-induced hyperglycemia in a nondiabetic middle-aged woman. A 64-year-old Indian woman with an extensive cardiovascular history was admitted for urosepsis. On admission, her blood glucose was 117 mg/dL. She was empirically started on gatifloxacin
Maria Agnes Dawis et al.
The Journal of antimicrobial chemotherapy, 51(5), 1203-1211 (2003-04-17)
To study the in vitro interaction of gatifloxacin in combination with gentamicin and with the beta-lactams cefepime, meropenem and piperacillin against clinical isolates of Stenotrophomonas maltophilia, Pseudomonas aeruginosa, Burkholderia cepacia, extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae, vancomycin-resistant Enterococcus faecium (VRE) and
Marva Seifert et al.
Antimicrobial agents and chemotherapy, 63(7) (2019-05-16)
Clinical phenotypic fluoroquinolone susceptibility testing of Mycobacterium tuberculosis is currently based on M. tuberculosis growth at a single critical concentration, which provides limited information for a nuanced clinical response. We propose using specific resistance-conferring M. tuberculosis mutations in gyrA together